Citizens JMP lowered the firm’s price target on Tela Bio (TELA) to $7 from $12 and keeps an Outperform rating on the shares. Sales in the quarter were impacted by several factors, including competitive rep poaching by smaller wound care companies offering significant comp benefits including guaranteed contracts, the analyst tells investors in a research note. The firm still believes that Tela’s two main biologic product platforms provide significant benefits to all constituents and that the premium growth profile here should be sustainable.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELA:
- TELA Bio’s Hold Rating: Challenges in Sales Force Turnover and Financial Outlook
- Tela Bio downgraded to Neutral from Overweight at Piper Sandler
- TELA Bio’s Strategic Shift to Biologics and Future Growth Potential Amidst Challenges
- TELA Bio Reports Strong 2024 Revenue Growth
- TELA Bio Projects Strong Revenue Growth for 2025
Questions or Comments about the article? Write to editor@tipranks.com